About 2025 Event
What You Missed at the 9th Tumor Models San Francisco Summit – the Only Summit that Gathered the Ecosystem of West Coast Preclinical & Translational Experts in Oncology
Assets are only becoming more expensive to develop, and with increasingly complex therapeutic modalities paving the way to a new era in oncology research, it is critical to de-risk the move to the clinic with more translational models.
5 Must-Attend Case Studies in 2025:
Interrogate the translational relevance of humanized mouse models and investigate data indicating translational relevance to optimize selection criteria
with Amgen
Navigate ADC activity in immunocompetent models across syngenic and humanized models to assess clinical relevance and optimize dosing
with AstraZeneca
Evaluate T cell engagers with additional functionality and selection rationale for humanized mouse models including PBMCs, transgenic and tox models
with Zymeworks
Optimize decision making in outsourcing or developing internal capabilities for translational studies through cost-benefit models across multiple modalities
with AstraZeneca
Explore combination dosing strategies in bispecifics and CAR-T therapies and evaluate toxicity in mouse models to optimize targeted cytokine therapies
with Regeneron